Vitestro's Aletta receives FDA De Novo clearance for autonomous phlebotomy robot entry into the U.S.
FDA opens new medical device category
The U.S. Food and Drug Administration (FDA) granted De Novo marketing clearance for Vitestro's Aletta for use in adult outpatient settings on August 19, 2026. Aletta is an autonomous robotic phlebotomy device that targets veins anatomically and performs the full phlebotomy process without direct operator intervention, making it the first standalone device of its kind. De Novo clearance applies to low- to moderate-risk devices without predicate products, and the FDA has also established special controls regarding labeling, performance, and clinical trials. This decision marks the beginning of a regulatory classification that future companies may reference via the 510(k) pathway, going beyond a single product approval.
Clinical data supports automation reliability
The multi-center ADOPT clinical trial, which formed the basis for the clearance, evaluated 1,633 outpatient participants. Aletta achieved a first-attempt venipuncture success rate of 94.5%. Success rates were 97.4% for obese patients, 92.7% for patients who reported difficult venous access, and 93.4% for patients aged 65 and older, demonstrating consistent performance in groups where manual phlebotomy is typically challenging. The hemolysis rate was 0.3%, and adverse event rate was 0.6%, with device-related adverse events being mild. Evaluated by the FDA as equal to or better than skilled phlebotomists, the competitive focus in the field is now shifting from vein detection to actual specimen quality and repeatable workflows.
Capacity expansion, not workforce replacement, is key
Aletta combines near-infrared imaging, Doppler ultrasound, and artificial intelligence with robotics to distinguish veins from arteries and automate the entire process—from tourniquet application to skin preparation, needle insertion and disposal, tube exchange, and bandage application. A trained phlebotomist initiates the session and can supervise up to three units simultaneously, with the device stopping the puncture if patient movement or safety violations are detected. Therefore, the initial economic value lies in expanding the processing capacity per phlebotomist, standardizing procedures, and reducing needle-stick exposure. However, adoption speed will also depend on factors such as equipment cost, space redesign, sterilization procedures, LIS integration, and consumable expenses.
First-mover advantage is significant, but commercial validation remains
Aletta received CE marking under the European Medical Device Regulation (MDR) in July 2024 and secured U.S. clearance in 2026, establishing a commercial foundation in both Europe and the U.S. Competitive technologies include VascuLogic's VenousPro, which performs infrared and ultrasound-guided robotic venipuncture. In the existing market, BD (BDX), Terumo (4543), Greiner Bio-One, and Sarstedt supply manual phlebotomy consumables and systems. The global blood collection device market is projected to grow from $9.26 billion in 2026 to $12.95 billion by 2030, though this figure includes a broad range of products such as tubes, needles, and blood bags. Vitestro raised a $70 million oversubscribed Series B funding round in March 2026, and post-clearance priorities include manufacturing scale-up and demonstrating real-world outpatient center throughput and cost savings.
FDA De Novo clearance positions Aletta as the first standalone autonomous phlebotomy robot at the approval stage and establishes special controls and regulatory benchmarks for future products. The ADOPT trial data from 1,633 patients and a 94.5% first-attempt success rate provide a benchmark for researchers not only in automated venipuncture but also in hemolysis rate (0.3%) and adverse event rate (0.6%). In the short term, the model of one phlebotomist supervising up to three units directly addresses staffing shortages and processing time issues in U.S. outpatient labs. In the medium to long term, Vitestro will compete with VenousPro in the $9.26 billion global blood collection device market in 2026 while adding an automation layer to the manual consumables ecosystem dominated by BD and Terumo. The $70 million Series B supports manufacturing and U.S. commercialization, but the next valuation inflection point for the company will depend on installed base, device utilization, cost per test, and recurring revenue structure.